Arbeitsgruppenleiter

Göhring, Gudrun

Göhring, Gudrun, Prof. Dr. med.

Arbeitsgruppenleiter

REBIRTH Unit Cytogenetic Profiling, Institut für Zell- und Molekularpathologie, MHH


Biography / About

Date of Birth:August, 1974
Function:Senior medical officer (leitende Oberärztin)

Education:

1994 - 1997Study of human medicine, Gustav von Guericke University, Magdeburg
1997 - 2003Study of human medicine, Hannover Medical School (MHH), Hannover
2003M.D., MHH, Hannover
2008Specialist of human genetics
2011Post-doctoral lecturing qualification (Habilitation)

Academic appointments and Research posts:

2003Assistant doctor, Department for Pediatric Haematology and Oncology, MHH, Hannover
2004Assistant doctor, Institute for Cell and Molecular Pathology, MHH, Hannover
2006Director of Cytogenetics, Institute for Cell and Molecular Pathology, MHH, Hannover
2009Senior physician, Institute for Cell and Molecular Pathology, MHH, Hannover
Since 2010Senior medical officer (leitende Oberärztin), Institute for Cell and Molecular Pathology (Institute for Human Genetics since 2014), MHH, Hannover

Other professional activities:

2007/2008Participation “Mentoring-Programm” MHH
2008/2009Participation “Aktiv in der Lehre”
Since 2009Member of “Kommission für Gleichstellung”
2010-2016Consultant for cytogenetics (Celgene/Onconova)
2015Cooperation on S2-guidelines “Humangenetic Diagnostics and Genetic Counselling”
Since 2017Member of the “Sektion IV”, MHH

Awards and Prizes:

2007Travel Award, ASH
2009Start-up funding for the habilitation, Medizinische Hochschule Hannover
2009Travel Award, ASH
2013 – 2017MDS joint project funded by Deutsche Krebshilfe, Bonn
Since 2012Exzellenzcluster REBIRTH EXC, 62/3, DFG

Major research interests:

  • Chromosomal instability
  • Complex karyotypes
  • Oncogentics
  • Haematological neoplasia

Selected Publications:

  1. Damm F, Lange K, Heuser M, Oberacker T, Morgan M, Wagner K, Krauter J, Schlegelberger B, Ganser A, Gohring G. Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28:e384-7.
  2. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E, Aul C, Schlegelberger B. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Annals of hematology 2010;89:365-74.
  3. Gohring G, Michalova K, Beverloo HB, Betts D, Harbott J, Haas OA, Kerndrup G, Sainati L, Bergstraesser E, Hasle H, Stary J, Trebo M, van den Heuvel-Eibrink MM, Zecca M, van Wering ER, Fischer A, Noellke P, Strahm B, Locatelli F, Niemeyer CM, Schlegelberger B. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 2010;116:3766-9.
  4. Lange K, Gadzicki D, Schlegelberger B, Gohring G. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study. Leukemia research 2010;34:1002-6.
  5. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, Gohring G. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes, chromosomes & cancer 2010;49:260-9.
  6. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Kramer A, Schwable J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Gohring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kuhlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature medicine 2010;16:198-204.
  7. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundstrom I, Strombeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Ryden T, Vyas P, Gohring G, Schlegelberger B, Johansson B, Hellstrom-Lindberg E, List A, Nilsson L, Jacobsen SE. Persistent malignant stem cells in del(5q) myelodysplasia in remission. The New England journal of medicine 2010;363:1025-37.
  8. Gohring G, Giagounidis A, Busche G, Hofmann W, Kreipe HH, Fenaux P, Hellstrom-Lindberg E, Schlegelberger B. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica 2011;96:319-22.
  9. Thomay K, Schienke A, Vajen B, Modlich U, Schambach A, Hofmann W, Schlegelberger B, Gohring G. Chromosomal instability and telomere shortening in long-term culture of hematopoietic stem cells: insights from a cell culture model of RPS14 haploinsufficiency. Cytogenetic and genome research 2014;142:14-20.
  10. Koenecke C, Gohring G (shared first authorship), de Wreede LC, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kroger N, EBMT MDSsotCMWPot. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica 2015;100:400-8.


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden